Press coverage about Medtronic plc. (NYSE:MDT) has been trending somewhat positive on Saturday, AlphaOne Sentiment Analysis reports. The research group, a subsidiary of Accern, rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Medtronic plc. earned a coverage optimism score of 0.04 on AlphaOne’s scale. AlphaOne also assigned media headlines about the medical technology company an impact score of 80 out of 100, indicating that recent media coverage is likely to have an effect on the company’s share price in the next few days.
Here are some of the media headlines that may have impacted AlphaOne Sentiment’s analysis:
- Medtronic : RESOLUTE ONYX(TM) 2.0 mm Clinical Study Meets Primary Endpoint in Extra-Small Vessels at One-Year (4-traders.com)
- Medtronic (MDT) RESOLUTE ONYX Meets Primary Study Endpoint (finance.yahoo.com)
- American Health Council Names Jeffrey Scifert, PhD to Industry Board (feeds.benzinga.com)
- Medtronic (MDT) Reports RESOLUTE ONYX(TM) 2.0 mm Clinical Study Meets Primary Endpoint – StreetInsider.com (streetinsider.com)
- Medtronic RESOLUTE ONYX(TM) 2.0 mm Clinical Study Meets Primary Endpoint in Extra-Small Vessels at One-Year (finance.yahoo.com)
A number of research analysts have weighed in on the stock. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Medtronic plc. in a research note on Wednesday, March 22nd. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 price target on shares of Medtronic plc. in a research report on Monday, February 6th. Vetr lowered shares of Medtronic plc. from a “strong-buy” rating to a “buy” rating and set a $81.00 price target on the stock. in a research report on Monday, January 23rd. Evercore ISI lifted their price target on shares of Medtronic plc. from $78.00 to $88.00 and gave the company a “buy” rating in a research report on Tuesday, February 21st. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $88.00 target price on shares of Medtronic plc. in a report on Friday, February 17th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and fifteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $87.17.
Medtronic plc. (NYSE:MDT) traded up 1.01% during mid-day trading on Friday, reaching $83.23. 4,780,448 shares of the company’s stock were exchanged. The company has a market cap of $113.93 billion, a PE ratio of 29.38 and a beta of 0.97. Medtronic plc. has a 52-week low of $69.35 and a 52-week high of $89.27. The stock has a 50-day moving average price of $81.99 and a 200 day moving average price of $78.42.
Medtronic plc. (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 21st. The medical technology company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.01. The company had revenue of $7.28 billion during the quarter, compared to analysts’ expectations of $7.22 billion. Medtronic plc. had a net margin of 14.63% and a return on equity of 12.36%. The business’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period last year, the business earned $1.06 EPS. Equities analysts predict that Medtronic plc. will post $4.58 earnings per share for the current fiscal year.
In other news, CEO Omar Ishrak sold 95,000 shares of Medtronic plc. stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $82.82, for a total transaction of $7,867,900.00. Following the completion of the sale, the chief executive officer now owns 645,616 shares of the company’s stock, valued at $53,469,917.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Hoedt Rob Ten sold 50,757 shares of the firm’s stock in a transaction on Monday, March 20th. The stock was sold at an average price of $81.58, for a total value of $4,140,756.06. Following the completion of the transaction, the executive vice president now owns 59,392 shares in the company, valued at approximately $4,845,199.36. The disclosure for this sale can be found here. Insiders sold 198,073 shares of company stock valued at $16,315,832 over the last three months. 0.25% of the stock is owned by company insiders.
About Medtronic plc.
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic plc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic plc. and related companies with MarketBeat.com's FREE daily email newsletter.